Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 18 of 18 results for palbociclib

  1. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020

  2. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. NICE approves routine use of drug combination for advanced breast cancer

    A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.

    News
    Last updated
    18 January 2024